Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

Insurance Guide · Last verified: May 22, 2026

Kaiser Wegovy Prior Authorization: Criteria, Coverage, and What to Do If You’re Denied

Published: May 23, 2026

By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers · Next scheduled review: August 22, 2026

Some links on this page are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. Coverage rules, prices, and medical facts are not influenced by partner relationships. We verify them against the original source before publishing and re-verify every quarter.

Reviewed against the Kaiser Permanente Northwest commercial Wegovy criteria PDF (effective February 5, 2026), the Kaiser Permanente Washington Provider E-News (January 2026), the Kaiser Permanente Mid-Atlantic Weight Management Agents PA form, Kaiser Southern California FEHB and PSHB 2026 formularies, the California Department of Managed Health Care’s IMR public FAQ, NovoCare Pharmacy pricing pages, Ro public pricing and coverage-checker pages, FDA Wegovy approval documents, and Medi-Cal Rx 2026 GLP-1 policy.

Your Kaiser Wegovy situation, at a glance

Find your situation to jump straight to the right answer.

Does Kaiser cover Wegovy in 2026?

Kaiser isn’t really one insurance company. It’s eight regional health plans plus federal benefit plans (FEHB and PSHB), and each one writes its own rules. So when a friend says “Kaiser approved my Wegovy in two weeks” and your coworker on Kaiser commercial in Seattle just got denied flat, both stories are true. They’re on different plans, different regions, different benefit designs.

To figure out whether Kaiser will cover your Wegovy, you have to clear three gates.

The three gates every Kaiser Wegovy request has to clear

When you know which gate is your problem, the right next move becomes obvious. Gate 1 means fighting Kaiser is usually wasted energy and the cash-pay path is the rational move. Gate 2 means you might genuinely not qualify yet. Gate 3 means you have a strong appeal.

Kaiser Wegovy coverage by region and plan: the verified matrix

We pulled the actual policy documents from every Kaiser region we could verify. Where we couldn’t verify with a public document, we flag it as [NEEDS PLAN-SPECIFIC VERIFICATION] — because the alternative is making something up, and that's not how we want to be wrong.

Verified Kaiser Wegovy coverage rows

Plan-specific verification required

What Kaiser actually requires for a Wegovy prior authorization approval

The six recurring Kaiser Wegovy criteria

These appear consistently across the Kaiser documents we verified. Kaiser Northwest is the most explicit, so we use it as the reference. Your region may apply these differently.

1. You’re an adult (18+). A separate pediatric pathway exists for ages 12–17 with stricter criteria.
2. Your prescription drug benefit covers weight-loss medications. This is the benefit-design check (Gate 1). If your plan doesn’t include this benefit, the standard pathway is closed.
3. No personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is an FDA Wegovy boxed-warning contraindication.
4. Current weight and BMI documented in your chart within the last 30 days. If you haven’t been weighed at Kaiser recently, get weighed before the PA goes in.
5. You’re currently following a diet and exercise program. Some Kaiser regions accept documentation of external programs (Weight Watchers, Noom, MyFitnessPal records). Mid-Atlantic’s PA form has specific lifestyle documentation requirements depending on BMI tier.
6. BMI threshold met: BMI ≥30, OR BMI ≥27 with at least one comorbidity: hypertension, type 2 diabetes, or hyperlipidemia.

The Kaiser Northwest step therapy ladder

Kaiser Northwest’s published criteria require a failed adequate trial of at least two of the following medications or combination therapies, OR a documented allergy, intolerance, or contraindication to all of them: phentermine, diethylpropion, topiramate, phentermine + topiramate (Qsymia), naltrexone + bupropion (Contrave). An “adequate trial” is defined as 3 months of treatment. That’s potentially 6 months of oral medication trials before Wegovy is on the table.

The cardiovascular risk reduction pathway (a different door)

If your standard weight-loss pathway is closed, there’s another door worth considering: cardiovascular risk reduction. The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight in March 2024, and many Kaiser regions have separate PA criteria for this indication.

Kaiser Northwest’s CV risk reduction criteria require:

• No personal/family history of MTC or MEN 2
• Patient does not have diabetes
• BMI ≥27
• Currently following diet and exercise program
• Aged 55–74
• History of STEMI (ST-elevation myocardial infarction) or Type 1 NSTEMI
• AND occurrence of a STEMI or Type 1 NSTEMI while on Ozempic 2 mg

That last requirement is restrictive — you need a second major cardiac event while already on Ozempic. For members who genuinely fit this profile, the CV pathway may be reviewed under different criteria, though it still requires documentation and plan-specific approval.

The MASH pathway (rare but real)

The FDA approved Wegovy for adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver scarring in 2025. Kaiser Northwest has a specific MASH PA pathway requiring:

• Diagnosis of MASH
• Hepatology provider consulted and endorsed use
• Fibrosis stage F2 or F3 confirmed by FibroScan, MRE, or biopsy within one year
• BMI ≥30 (or 27+ with T2D/HTN/hyperlipidemia)
• Failed step therapy trials
• Failed Ozempic trial
• Patient is not taking resmetirom
• Patient does not have F4 fibrosis or cirrhosis

If you have liver issues in your chart and you’re getting nowhere with the weight-loss pathway, ask your PCP about a hepatology consult to evaluate for MASH. It’s not a workaround — it requires actual liver fibrosis documented on imaging — but it’s a legitimate alternative coverage indication. We cover other ways MASH and CV risk reduction change the coverage math here.

The renewal criteria (keeping coverage after year one)

Getting approved once doesn’t lock you in forever. Kaiser re-reviews Wegovy coverage every 12 months. The Northwest renewal criteria are simpler:

• Updated weight and BMI documented
• Achieved AND maintained ≥5% weight loss since starting Wegovy

If you don’t hit 5% in your first year, Kaiser likely won’t renew. That’s not unique to Kaiser — most insurers use a 5% benchmark — but it’s worth knowing before you start.

Does Kaiser cover the Wegovy pill?

The FDA approved the Wegovy pill (oral semaglutide) in December 2025. The reasonable assumption is that an oral version should be simpler to approve than an injection. That’s not actually how Kaiser’s PA works. Kaiser Northwest’s oral Wegovy criteria layer additional requirements on top of the injectable criteria — the patient must demonstrate an inability to safely use the injectable form in specific circumstances. The oral form isn’t positioned as a simpler default; it’s positioned as an alternative when injection isn’t appropriate.

Kaiser Mid-Atlantic’s PA form makes this explicit: the form specifically asks whether the patient has documented trypanophobia when oral Wegovy tablets are requested. If you can take the injection, Kaiser’s structure pushes you toward the injection. The pricing on cash-pay options does favor the pill (NovoCare lists $149/month for 1.5 mg and 4 mg pill vs. $349/month standard for the pen), but Kaiser’s PA bar is similar or higher for the pill. We go deeper on this in Wegovy Pill vs Injection: Cost & Results 2026.

How long Kaiser Wegovy prior authorization really takes

Most articles tell you Kaiser Wegovy PA takes “3 to 14 business days.” Technically true. Completely misleading. That window is just the time Kaiser’s PA review team takes to decide on a completed submission. It doesn’t include any of the work that has to happen before that submission lands on their desk.

The Kaiser Wegovy timeline math

Best case total: ~4 weeks (for someone with extensive prior medication history already in their chart and a region that doesn’t require an Ozempic trial). Worst case total: 6 months or more (for someone starting fresh in a region requiring full step therapy and a weight management program).

How to compress the timeline legitimately

• Bring outside records to your first PCP visit. Prior weight programs (Weight Watchers receipts, Noom history, gym membership records), prior medication trials from other doctors, lab results — all of it can satisfy step-therapy and lifestyle requirements you’d otherwise have to redo at Kaiser.
• Document all comorbidities at the first visit. Many Kaiser charts undercount weight-related conditions because nobody asked. If you have high blood pressure or borderline diabetes, make sure it’s coded properly (ICD-10 codes: I10 for hypertension, E11.9 for type 2 diabetes, E78.5 for hyperlipidemia).
• For Mid-Atlantic members: start the documented lifestyle intervention immediately at your first PCP visit. The 90-day clock doesn’t start until your prescriber documents it.
• Ask the right question. Instead of “can I get Wegovy?”, ask: “what specific documentation do you need in my chart before submitting a Wegovy PA, and what’s the fastest legitimate path?” That gets a different conversation than the standard scripted response.

How to prepare your Kaiser Wegovy PA request so it actually gets approved

The Kaiser Wegovy PA documentation checklist

Bring this to your first PCP visit (or send via MyChart message before the visit):

The PCP message template that works

Use this via Kaiser’s secure messaging or as the conversation opener at the first visit:

This message signals you’ve done your homework, asks for benefit confirmation before clinical work, anticipates the step therapy requirement, explicitly asks about documentation, and frames denial avoidance as a shared goal — not a fight.

What NOT to say

• “I just want to try Wegovy because I saw it online.” Sets off the cosmetic-use red flag.
• “Can you prescribe it even if Kaiser doesn’t cover it?” Most Kaiser doctors will say no.
• “I don’t know my BMI but can we submit anyway?” The PA will get denied for incomplete documentation.
• “My friend got it with no problem.” Different plan, different region, irrelevant to your case.

Why Kaiser denied your Wegovy — the 7 most common reasons decoded

Most members read their Kaiser denial letter, see “does not meet medical necessity criteria,” and give up. That phrase is doing a lot of work. It can mean any of seven different things, and the right next step depends on which one.

How to read your Kaiser denial letter in the first 24 hours

• Save everything. The denial letter, the original PA submission, your prescriber’s notes, any messages with Kaiser member services. If this goes to external appeal, the regulator will want the complete paper trail.
• Note the deadlines. Most Kaiser internal appeals must be filed within 180 days of the denial. California DMHC IMRs must be filed within 6 months of the final internal denial. Federal external reviews have a 4-month window after final internal denial. Missing a deadline kills the appeal, period.
• Don’t argue with Kaiser member services on the phone. Phone calls don’t create a record and they don’t trigger the formal appeal process. Start the appeal in writing — through Kaiser’s secure messaging, the appeal form on kp.org, or a certified letter.

How to appeal a Kaiser Wegovy denial — and when California DMHC IMR can help

Stage 1: The internal Kaiser appeal

File within 180 days of the denial letter. Submit in writing — Kaiser’s secure messaging on kp.org, the appeal form, or certified mail. Phone calls don’t count.

Include in your appeal:

• A cover letter explaining what’s being appealed and why
• The original denial letter
• BMI and comorbidity documentation (with ICD-10 codes)
• Step therapy documentation (or contraindication documentation)
• Lifestyle program documentation
• A medical necessity letter from your PCP citing FDA-labeled indications for Wegovy
• Any relevant outside records Kaiser doesn’t already have

Request the appeal be considered as both an internal grievance and a coverage determination. Kaiser must respond within 30 days for standard appeals, and within 72 hours for urgent cases (urgency means delay would seriously jeopardize your health).

Stage 2 (California): The DMHC Independent Medical Review

If Kaiser upholds the denial, California members can request an Independent Medical Review through the Department of Managed Health Care. The IMR is free, and decisions are typically issued in 30 days for standard cases (7 days for urgent).

The DMHC IMR walkthrough

1. Exhaust Kaiser’s internal appeal first. Usually required before DMHC will accept an IMR (limited exceptions for urgent care or imminent harm).
2. File at dmhc.ca.gov. Go to “File a Complaint” → “Request an Independent Medical Review.” The form is free.
3. Submit your documentation. Original denial, internal appeal response, medical records, prescriber’s medical necessity letter, and a personal statement.
4. DMHC assigns an Independent Review Organization. A panel of independent physicians (not Kaiser, not DMHC) reviews your case.
5. Decision issued. Standard cases: 30 days. Urgent: 7 days.
6. If overturned, Kaiser must cover the medication. No further negotiation. The IMR ruling is binding.

Appeal pathways for non-California Kaiser members

The Kaiser Wegovy appeal letter template

This template is informational, not legal or medical advice. Use it only after confirming the statements match your actual records and your clinician’s judgment. Edit anything that doesn’t match your situation.

[Your name]
[Address]
[Kaiser member ID]

[Date]

Kaiser Permanente Member Appeals
[Regional appeal address — find on kp.org/appeals or your denial letter]

RE: Appeal of Prior Authorization Denial — Wegovy (semaglutide)
Member ID: [your ID]
Denial Date: [date]
Reference Number: [from denial letter]

Dear Kaiser Permanente Appeals Department:

I am formally appealing the prior authorization denial for Wegovy
(semaglutide) issued on [date]. I am requesting that this appeal be
considered both as an internal grievance and as a coverage
determination.

My situation:

Current weight: [weight], documented [date]
Current BMI: [BMI]
Diagnoses (ICD-10):
- [e.g., E66.01 - Morbid (severe) obesity due to excess calories]
- [e.g., I10 - Essential (primary) hypertension]
- [e.g., E78.5 - Hyperlipidemia, unspecified]

Step therapy trials completed:
- [Medication 1]: [start date] to [end date], discontinued due to
  [inadequate response / intolerance / contraindication], documented
  by [provider]
- [Medication 2]: [start date] to [end date], discontinued due to
  [reason], documented by [provider]

Lifestyle interventions:
- [Program 1]: [dates], documentation attached
- [Program 2]: [dates], documentation attached

Medical necessity:

My PCP, [name], has determined Wegovy is medically necessary for my
care based on my BMI, comorbidities, and prior treatment history.
[Attach PCP medical necessity letter citing relevant FDA-labeled
indications.]

I am requesting that Kaiser approve Wegovy under my plan. If the
denial is upheld, I am requesting all documentation needed to pursue
external review.

Sincerely,
[Your name]

Attachments:
- Original PA denial letter
- BMI documentation (last 30 days)
- Diagnoses chart notes
- Step therapy documentation
- PCP medical necessity letter
- Lifestyle program documentation

What to do if Kaiser won’t budge: FDA-approved Wegovy options at verified prices

A note: this page is specifically about FDA-approved Wegovy. Compounded semaglutide is a completely different conversation. We don’t blur those two, and we won’t recommend compounded GLP-1s on a page where you’re committed to brand-name FDA-approved medication.

Option 1: NovoCare Pharmacy direct (the cheapest medication-only path)

NovoCare is Novo Nordisk’s own direct-to-patient pharmacy. They sell their own medication at their own cash-pay prices. You bring your own prescription — NovoCare doesn’t include the doctor visit.

Option 2: Ro telehealth (the simplest one-stop path)

This is the most common path for Kaiser members whose Kaiser pathway is closed.

• The Insurance Coverage Checker. Ro publicly offers a free GLP-1 Insurance Coverage Checker. You submit your insurance information, Ro contacts your plan, and Ro sends a personalized coverage report that may include whether prior authorization is required. This is the fastest legitimate way to know whether your Kaiser plan is actually closed or just complicated.
• FDA-approved options. Ro publicly lists FDA-approved Wegovy pill and Wegovy pen on its weight-loss program pricing page, alongside Zepbound and Foundayo.
• Ro pricing (verified on ro.co as of May 2026): $39 the first month; then $149/month for ongoing Ro Body membership, OR as low as $74/month with annual plan paid upfront. Medication is billed separately. Ro currently lists Wegovy pill starting at $149 for the first month and $199–$299 thereafter, and Wegovy pen at $199 for the first month and $199–$399 thereafter.

Option 3: Sesame Care (the provider-choice alternative)

Sesame is a healthcare marketplace where you pick your own provider for a visit fee, and the provider can prescribe FDA-approved medications. Sesame publicly lists Wegovy pill, Wegovy pen, Zepbound, Zepbound KwikPen, Ozempic, and Foundayo on its online weight-loss pages. Visit-based model — no membership lock-in. You pick your own clinician. Pricing is visit fee plus medication.

Sesame is a strong fit for Kaiser members who want provider choice, a specific clinician, or a visit-based model instead of a subscription.

Side-by-side comparison: Kaiser PA vs. alternatives

What Wegovy actually costs through Kaiser (and without it)

HSA/FSA eligibility

Wegovy may be HSA/FSA reimbursable when prescribed for a medical condition. Confirm eligibility with your HSA/FSA administrator and keep itemized receipts (medication name, dose, date filled, amount paid). Rules can vary by administrator and documentation type — a quick call to your benefits administrator saves headaches at tax time.

Kaiser Wegovy: real questions, real answers

What we verified and how

What we did not verify

• Kaiser Colorado, Georgia, and Hawaii Wegovy criteria PDFs: These regions don’t consistently publish member-facing criteria on the public website. Your fastest path to clarity is your specific plan’s Evidence of Coverage or a call to Kaiser member services.
• Employer-specific plan tiers and copays: These vary widely across employer groups. We cite verified ranges where they exist and direct readers to their specific plan documents otherwise.
• Every Kaiser California plan design: Self-funded employer plans can override the Commercial HMO formulary defaults. Verify with HR or member services.

Related guides on The RX Index

• Does Medicare cover Wegovy for weight loss? 2026
• Wegovy Savings Card: Qualify, Cost & Enroll (2026)
• Wegovy Pill vs Injection: Cost & Results 2026
• Medicaid GLP-1 Coverage by State (2026)
• GLP-1 Providers That Accept Kaiser: 3 Paths
• GLP-1 Providers That Help With Prior Authorization
• Foundayo (Orforglipron) Availability & Cost 2026
• Does Kaiser Cover Wegovy? 2026 Plan Check
• Does Kaiser Cover Zepbound? 2026 Plan Check
• How to Appeal a Wegovy Denial: Step-by-Step Guide